Since long-acting analogues or agonists of FGF21 hold great promise as potential therapeutic targets for the management of fundus diseases like diabetic retinopathy14, as well as neuropathic disease such as Alzheimer’s disease and Parkinson’s disease46,47, based on our findings, FGF21 may serve as a viable approach for improving visual outcomes in RAO. The gene discussed is FGF21; the disease is early-onset autosomal dominant Alzheimer disease.